Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.

Area of Science:

• Immunotherapy
• Cellular Therapy
• Molecular Engineering

Background:

• Chimeric antigen receptor (CAR) T cells offer potent therapies for hematological malignancies but are associated with severe side effects.
• Current CAR T-cell therapies face challenges in tumor specificity and controllability, leading to off-target reactions.

Purpose of the Study:

• To establish a novel humanized artificial receptor platform, RevCARs, for enhanced safety, controllability, and tumor specificity in CAR T-cell therapy.
• To engineer CAR T cells that can be steered by bispecific targeting molecules (TMs) for flexible and precise cancer targeting.

Main Methods:

• Development of RevCAR genes encoding small surface receptors without inherent antigen-binding domains.
• Utilizing bispecific targeting molecules (TMs) to direct RevCAR T-cell activity.
• Construction of polycistronic vectors for efficient gene delivery of RevCARs.

Main Results:

• RevCAR T cells demonstrated efficient tumor cell killing capabilities.
• RevCAR T cells could be effectively steered by TMs, allowing flexible redirection against multiple tumor targets.
• Demonstrated combinatorial targeting strategies using RevCAR T cells with "OR" and "AND" gate logic.

Conclusions:

• The RevCAR platform offers a promising approach to enhance the safety and efficacy of CAR T-cell therapy.
• RevCARs provide a controllable and flexible system for redirecting T-cell activity, enabling sophisticated targeting strategies.
• This technology has the potential to overcome limitations of current CAR T-cell therapies and broaden their clinical applicability.